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titioners, psychiatrists, psychologists and social workers,
medications and ambulance services. Hospitalization
days were obtained from the Canadian Institute of Health
Information, and per diem costs were taken from the
London Health Sciences Centre in Ontario and from the
Psychiatric Specialty Hospital Cost Study. Ambulatory
visits were estimated from the Canadian Disease and
Therapeutic Index of Intercontinental Medical Statistics;
their unit costs correspond to weighted average costs
from 5 Canadian provinces. Medication costs were esti-
mated from the Compuscript of IMS. Productivity losses
were based on length of depressive episodes obtained
from the National Population Health Survey. Based on
the literature, we assumed that 1.8 working days/week
were lost during their episode. For the remaining working
days, productivity was assumed at 80%. Premature mor-
tality costs by suicide were estimated assuming that 60%
of suicides were caused by depression. Potential years of
life lost were multiplied by average earning taking into
account increase of labour productivity, employment rate
and a 5% discount rate.
RESULTS: The total cost of depression in Canada in
2000 was approximately $5.4 billions. Direct costs were
$2.1 billions or 39.5% of the burden. Indirect costs were
estimated at $3.2 billions. Mortality costs were $831 
millions, or 15.4%, and productivity losses $2.4 billions,
or 45.1%.
CONCLUSION: Based on these estimates, the burden of
depression in Canada is important. This sheds light on
the economic impact of this incapacitating mental disease.
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OBJECTIVES: The purpose of this study is to assess 
the cost-effectiveness of escitalopram, a new selective
serotonin reuptake inhibitor (SSRI), versus citalopram,
ﬂuoxetine, and venlafaxine in Sweden.
METHODS: Cost-effective analysis is performed using 
a two-path decision analytic model with a 6-month
horizon. Patients start at the primary path, and are
referred to specialist care in the secondary care path. This
is typical of a GP/Psychiatrist setting. Model inputs
include drug-speciﬁc probabilities from comparative trial
data, published literature, and a clinical experts’ panel.
The primary outcome measure is ‘success’, deﬁned as
patients in remission 6 months after the start of treat-
ment. The model combines success rates and expected
costs to calculate the cost-effectiveness ratios. The 
estimated number of patient episodes during each drug
treatment (using IMS volume sales) are combined with
the average 6-month per-patient expected costs of treat-
ment (total and drug costs) to estimate the effect of the
introduction of escitalopram on the health care budget.
RESULTS: Treatment of Major Depressive Disorder with
escitalopram yielded a lower expected cost and greater
effectiveness compared to other SSRIs and SNRIs. The
expected success rate (remission) was 63.5% for esci-
talopram, compared to 57.2%, 57.0%, and 61.1% for
citalopram, ﬂuoxetine, and venlafaxine, respectively.
Average expected total medical costs per patient are
similar for escitalopram (SEK 15,670) and venlafaxine
(SEK 16,580), and somewhat higher for citalopram and
ﬂuoxetine (SEK 18,860 and 19,050 respectively). Bud-
getary impact shows that the increase in drug costs
(increase in Drug Budget estimated at SEK 44 million) is
more than offset by the decrease in other health care costs
(decrease in total Health Care Budget estimated at SEK
543 million).
CONCLUSIONS: Escitalopram is a cost-effective 
treatment alternative to citalopram, ﬂuoxetine, and ven-
lafaxine. The results of this study indicate that increased
utilisation of escitalopram might reduce health care costs
in Sweden.
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While several studies have measured the direct costs of
informal caregiving for Alzheimer’s patients, indirect
costs such as income losses to working caregivers and
productivity costs to their employers have received little
attention.
OBJECTIVES: This study estimates employment-related
costs of caregiving for Alzheimer’s patients and the effects
of the cholinesterase inhibitor, rivastigmine, on these
costs.
METHODS: Employment-related costs of informal
Alzheimer’s caregiving were imputed from several studies
on Alzheimer’s and caregiving, including ﬁndings from
the NAC/AARP survey of family caregivers. Published
employment-related costs, which applied to all caregivers
of the elderly, were made Alzheimer’s speciﬁc and differ-
entiated by disease stage. These estimates were linked to
clinical trial scores (Progressive Deterioration Scale) for
rivastigmine to estimate savings in employment-related
costs associated with this Alzheimer’s therapy.
RESULTS: Productivity costs to employers per working,
informal Alzheimer’s caregiver are $2,187 yearly, while
yearly income losses to working caregivers are $11,525.
Total productivity costs to employers are $1.89 billion
annually while total income losses to caregivers are $9.96
billion annually. Employment-related costs are highest 
for informal caregivers of Alzheimer’s patients in the
moderate disease stage because of a higher concentration
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of these patients in the community compared to patients
in the severe stage who tend to be institutionalized. Based
on its slowing of Alzheimer’s patient deterioration,
rivastigmine would save annually $268 million (14.2%)
of total productivity costs to employers and $1.41 billion
(14.2%) of total income losses to caregivers. Rivastig-
mine’s effects in slowing Alzheimer’s patient deterioration
are strongest in the moderate disease stage. Coupled with
higher employment-related costs in this stage, rivastig-
mine’s cost-saving effects would also be highest in the
moderate disease stage.
CONCLUSION: Employment-related costs of informal
Alzheimer’s caregiving are substantial. Therapies such as
rivastigmine can signiﬁcantly reduce these costs, particu-
larly in the moderate disease stage where costs and
rivastigmine’s effects are greatest.
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OBJECTIVES: The purpose of this study is to estimate
the impact of anxiety on absenteeism and employment 
in the United States using the 1997 Medical Expenditure
Panel Survey.
METHODS: Anxiety cases were deﬁned by self-report 
by survey respondents who saw a physician during the
previous year for a condition and recorded as a three 
digit ICD-9 code (Anxiety disorders = 300). National
population estimates were derived from patient level
weights as determined by a nationally representative
sample of the non-institutionalized civilian population of
the United States in 1997. Descriptive analyses were used
to examine individual demographic, socioeconomic, and
co-morbidity characteristics of those respondents with
anxiety.
RESULTS: Of the 1997 US representative population of
34,551 survey respondents from the MEPS analysis, 848
persons, representing 684,312 persons (2.5% of the US
population), reported having anxiety. Anxiety respon-
dents were more likely to be female (69.2%), Caucasian
(83.6%), and older than the overall population (mean age
44 years vs. 33 years). Among respondents aged 18–64
years, persons with anxiety were less likely to work than
those without anxiety (males 59.1% vs. 70.8%; females
53.5% vs. 56.9%). Those persons reporting anxiety were
more likely to have missed days from work 39.1% vs.
28.2% for females and 35.9% vs. 27.5% for males.
Persons with anxiety were more likely to change jobs
through the year and a half interview reference period
(57.8% vs.49.2% for females; 63.9% vs. 57.4% for
males).
CONCLUSIONS: Differences are seen at the workplace
in patients with and without anxiety disorders. Patients
with anxiety most often are female and have a greater fre-
quency of not being employed, missing time from work,
and changing jobs.
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OBJECTIVE: An estimated 50% of Americans are
exposed to at least one traumatic event in a lifetime. Of
those, 20% experience post-traumatic stress disorder
(PTSD). Approximately 50% of patients with PTSD have
comorbid major depression disorder. This study exam-
ined the cost differential between patients with major
depressive disorder (MDD) only, PTSD only and patients
with comorbid MDD and PTSD.
METHODS: A retrospective study of patients with MDD
and PTSD was performed using 1996 to 1999 claims
from the MarketScan Database, with private sector health
data from approximately 100 payers. Three cohorts of
patients were created: 1) patients with MDD (ICD-9-CM
296.2, 296.3, 300.4, or 311); 2) patients with PTSD
(ICD-9-CM 309.81); and 3) patients with both MDD and
PTSD. Patients had to also have a prescription drug claim
for an antidepressant within 30 days of diagnosis. During
the 6 month follow-up, healthcare utilization and expen-
ditures for inpatient, outpatient, emergency room, and
outpatient drugs were calculated. Total expenditures were
compared. ANOVA was used to assess the statistical 
signiﬁcance of differences in expenditures.
RESULTS: A total of 24,955 patients with fee-for-service
health coverage were identiﬁed. Of those, 24,156 were
diagnosed with MDD, 196 with PTSD, and 603 had 
co-occurring MDD and PTSD. The mean total expendi-
ture for patients with MDD, PTSD, and MDD with PTSD
were $3,407, $3,714, $5,723 respectively (p < 0.05).
PTSD was signiﬁcantly associated with increased expen-
ditures after stratifying for gender, age, and geographic
region.
CONCLUSION: Costs associated with MDD and PTSD
are substantial. The total health care expenditures of
patients with PTSD were signiﬁcantly higher than 
expenditures for patients with MDD alone. Patients 
with comorbid depression and PTSD had signiﬁcantly
increased expenditures than patients with one condition.
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